Kelsey S. Moore, PhDโ€™s Post

View profile for Kelsey S. Moore, PhD, graphic

Next-Generation Histopathology | Life Science Marketing

๐๐จ๐จ๐ฌ๐ญ ๐ฐ๐จ๐ฆ๐ž๐ง'๐ฌ ๐ก๐ž๐š๐ฅ๐ญ๐ก ๐ญ๐จ ๐›๐จ๐จ๐ฌ๐ญ ๐ญ๐ก๐ž ๐ž๐œ๐จ๐ง๐จ๐ฆ๐ฒ ๐Ÿ‘› McKinsey & Company illustrated the health & economic burden of being female in a recent analysis (linked in comments). Highlights of the XX experience: โšฌ Longer life expectancy than males, but more years of "poor health" โšฌ Dominance in multiple chronic diseases (depression, autoimmune, connective tissue, etc.) โšฌ Existing treatments that are less effective and less accessible โšฌ Diagnosis requires ~2.5 more years for over 700 diseases โšฌ > 55% of health burden during working age (20-64) โšฌ More research on diseases of mortality than morbidity ๐˜˜๐˜ถ๐˜ข๐˜ฏ๐˜ต๐˜ช๐˜ง๐˜ช๐˜ฆ๐˜ฅ ๐˜ฃ๐˜บ ๐˜ฅ๐˜ช๐˜ด๐˜ข๐˜ฃ๐˜ช๐˜ญ๐˜ช๐˜ต๐˜บ ๐˜ข๐˜ฅ๐˜ซ๐˜ถ๐˜ด๐˜ต๐˜ฆ๐˜ฅ ๐˜ญ๐˜ช๐˜ง๐˜ฆ ๐˜บ๐˜ฆ๐˜ข๐˜ณ๐˜ด (๐˜‹๐˜ˆ๐˜“๐˜ ๐˜ด), ๐˜ค๐˜ญ๐˜ฐ๐˜ด๐˜ช๐˜ฏ๐˜จ ๐˜ต๐˜ฉ๐˜ฆ ๐˜จ๐˜ข๐˜ฑ ๐˜ช๐˜ด ๐˜ด๐˜ถ๐˜จ๐˜จ๐˜ฆ๐˜ด๐˜ต๐˜ฆ๐˜ฅ ๐˜ต๐˜ฐ ๐˜ฃ๐˜ฐ๐˜ฐ๐˜ด๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฆ๐˜ค๐˜ฐ๐˜ฏ๐˜ฐ๐˜ฎ๐˜บ ๐˜ฃ๐˜บ ๐˜ฐ๐˜ฏ๐˜ฆ ๐˜ต๐˜ณ๐˜ช๐˜ญ๐˜ญ๐˜ช๐˜ฐ๐˜ฏ ๐˜ฅ๐˜ฐ๐˜ญ๐˜ญ๐˜ข๐˜ณ๐˜ด ๐˜ฃ๐˜บ 2040. ๐Ÿ’ญ Requiring female subjects in preclinical research and drug development will start closing the gap, in my opinion. How else?

To view or add a comment, sign in

Explore topics